Insider Trades
Common-stock transactions that officers, directors and 10% owners of healthcare companies report to the SEC on Form 4, from 2006 to today, newest first.
Insider filings are public records and are not a recommendation.
Results
25+ transactions, newest first
| Date | Insider | Relationship | Company | Transaction | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 4,000,000 | $0.50 | $2,000,000 | 6,779,440Direct | Form 4 filed 17 Feb 2026, on sec.gov (opens in a new tab)Filed 17 Feb 2026 | |
| Gurrola Sandra M | Sr. VP of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherM · Option or derivative exercised or converted | 30 | Not reported | No price reported | 110Direct | Form 4 filed 7 Jul 2025, on sec.gov (opens in a new tab)Filed 7 Jul 2025 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 21,241,163 | $0.10 | $2,124,116.30 | 41,659,743Direct | Form 4 filed 11 Jun 2025, on sec.gov (opens in a new tab)Filed 11 Jun 2025 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 3,768,397 | $0.10 | $376,839.70 | 20,401,602Direct | Form 4 filed 4 Apr 2025, on sec.gov (opens in a new tab)Filed 4 Apr 2025 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherC · Conversion of a derivative security | 2,819,546 | $0.50 | $1,409,773 | 16,628,123Direct | Form 4 filed 5 Nov 2024, on sec.gov (opens in a new tab)Filed 5 Nov 2024 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 1,562,988 | Not reported | No price reported | 13,808,577Direct | Form 4 filed 5 Nov 2024, on sec.gov (opens in a new tab)Filed 5 Nov 2024 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 5,420,823 | Not reported | No price reported | 12,245,589Direct | Form 4 filed 5 Nov 2024, on sec.gov (opens in a new tab)Filed 5 Nov 2024 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 1,237,762 | Not reported | No price reported | 6,824,766Direct | Form 4 filed 5 Nov 2024, on sec.gov (opens in a new tab)Filed 5 Nov 2024 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 4,768,783 | Not reported | No price reported | 5,587,004Direct | Form 4 filed 5 Nov 2024, on sec.gov (opens in a new tab)Filed 5 Nov 2024 | |
| Cherington Charles | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 261,756 | Not reported | No price reported | 818,221Direct | Form 4 filed 5 Nov 2024, on sec.gov (opens in a new tab)Filed 5 Nov 2024 | |
| Gurrola Sandra M | Sr. VP of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherF · Shares withheld to pay tax or exercise price | 180 | $1.94 | $349.20 | 1,185Direct | Form 4 filed 25 Jun 2024, on sec.gov (opens in a new tab)Filed 25 Jun 2024 | |
| Gurrola Sandra M | Sr. VP of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherM · Option or derivative exercised or converted | 437 | Not reported | No price reported | 1,365Direct | Form 4 filed 25 Jun 2024, on sec.gov (opens in a new tab)Filed 25 Jun 2024 | |
| Gurrola Sandra M | Vice President of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherF · Shares withheld to pay tax or exercise price | 179 | $2.48 | $443.92 | 928Direct | Form 4 filed 23 Jun 2023, on sec.gov (opens in a new tab)Filed 23 Jun 2023 | |
| Gurrola Sandra M | Vice President of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherM · Option or derivative exercised or converted | 438 | Not reported | No price reported | 1,107Direct | Form 4 filed 23 Jun 2023, on sec.gov (opens in a new tab)Filed 23 Jun 2023 | |
| HALPERN JOHN D | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 335,920 | $3.28 | $1,101,817.60 | 450,961Indirect, As trustee of family trust | Form 4 filed 5 Dec 2022, on sec.gov (opens in a new tab)Filed 5 Dec 2022 | |
| Singer Nicholas Jason | Director | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 212,464 | $3.28 | $696,881.92 | 266,214Indirect, By Pacific Premier Trust, Custodian, FBO Nicholas J. Singer | Form 4 filed 6 Dec 2022, on sec.gov (opens in a new tab)Filed 6 Dec 2022 | |
| Singer Nicholas Jason | Director | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 70,822 | $3.28 | $232,296.16 | 121,822Indirect, By Purchase Capital LLC | Form 4 filed 6 Dec 2022, on sec.gov (opens in a new tab)Filed 6 Dec 2022 | |
| Cherington Charles | Director, 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 261,756 | $3.28 | $858,559.68 | 556,465Direct | Form 4 filed 6 Dec 2022, on sec.gov (opens in a new tab)Filed 6 Dec 2022 | |
| Sidhu Roger | Chief Medical Officer | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherM · Option or derivative exercised or converted | 20,163 | Not reported | No price reported | 20,163Direct | Form 4 filed 21 Sep 2022, on sec.gov (opens in a new tab)Filed 21 Sep 2022 | |
| DAmour Kevin | Chief Scientific Officer | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherF · Shares withheld to pay tax or exercise price | 6,077 | $0.55 | $3,342.35 | 11,496Direct | Form 4 filed 29 Jun 2022, on sec.gov (opens in a new tab)Filed 29 Jun 2022 | |
| DAmour Kevin | Chief Scientific Officer | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherM · Option or derivative exercised or converted | 17,573 | Not reported | No price reported | 17,573Direct | Form 4 filed 29 Jun 2022, on sec.gov (opens in a new tab)Filed 29 Jun 2022 | |
| Gurrola Sandra M | Vice President of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherF · Shares withheld to pay tax or exercise price | 3,586 | $0.48 | $1,721.28 | 13,367Direct | Form 4 filed 23 Jun 2022, on sec.gov (opens in a new tab)Filed 23 Jun 2022 | |
| Gurrola Sandra M | Vice President of Finance | Ernexa Therapeutics Inc.ERNA, ERNAW | OtherM · Option or derivative exercised or converted | 8,750 | Not reported | No price reported | 16,953Direct | Form 4 filed 23 Jun 2022, on sec.gov (opens in a new tab)Filed 23 Jun 2022 | |
| DENNY GEORGE P III | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 1 | $11.99 | $11.99 | 3Indirect, By Spouse | Form 4 filed 20 Aug 2021, on sec.gov (opens in a new tab)Filed 20 Aug 2021 | |
| DENNY GEORGE P III | 10% owner | Ernexa Therapeutics Inc.ERNA, ERNAW | BuyP · Open-market or private purchase | 1 | $14.11 | $14.11 | 2Indirect, By Spouse | Form 4 filed 20 Aug 2021, on sec.gov (opens in a new tab)Filed 20 Aug 2021 |
Source: SEC EDGAR Form 4 filings and the SEC Insider Transactions Data Sets (2006 onward). Each row links to its Form 4 filing. Values are shares times the reported price. Nothing here is investment advice.